Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02968732 · ClinicalTrials.gov registry record · NA

Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder

A NA study of Urothelial Carcinoma, sponsored by Fox Chase Cancer Center.

Active
Registry status
NA
Development phase
65
Enrollment target
1
Study location

NCT02968732 is a NA study of Urothelial Carcinoma that is active but no longer recruiting, run by Fox Chase Cancer Center. The registered enrollment target is 65 participants, below the 238-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02968732, a NA study of Urothelial Carcinoma, is active but no longer recruiting, sponsored by Fox Chase Cancer Center.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
65 participants
Enrollment target
1
Study location

Study Summary

A prospective, investigational study to assess the accuracy of standardized cystoscopic evaluation with tissue sampling performed immediately prior to definitive radical cystectomy to predict pathologic tumor stage and identify patients who may benefit from bladder preservation therapy.

Conditions Studied

Interventions

  • PROCEDURE Radical Cystectomy

Study Locations (1)

Pennsylvania

  • Fox Chase Cancer Center - Philadelphia

Trial Details

FieldValue
Enrollment Target 65 participants
Start Date 2016-11-11
Est. Completion 2027-04-01
Phase NA

Sponsor

Fox Chase Cancer Center

183 total trials

What the Registry Record Tells You About NCT02968732

The ClinicalTrials.gov registry entry for NCT02968732 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 238-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (73% lower). The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Urothelial Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Radical Cystectomy is the first listed.

NCT02968732 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT02968732 about?

NCT02968732 is a clinical study titled "Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder". A prospective, investigational study to assess the accuracy of standardized cystoscopic evaluation with tissue sampling performed immediately prior to definitive radical cystectomy to predict pathologic tumor stage and identify patients who may benefit from bladder preservation therapy.

What is the current status of trial NCT02968732?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 65 participants. The study started on 2016-11-11. Estimated completion is 2027-04-01.

What conditions does trial NCT02968732 study?

This clinical trial studies the following conditions: Urothelial Carcinoma.

What interventions are being tested in trial NCT02968732?

The interventions under investigation include: Radical Cystectomy (PROCEDURE).

Who is sponsoring clinical trial NCT02968732?

This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02968732 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Urothelial Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.